Human Albumin Csl Behring

Human Albumin Csl Behring is a sterile intravenous solution containing human plasma protein (human albumin) as its active ingredient. The product is supplied without a disclosed strength and is intended for infusion by healthcare professionals. Classified as a plasma protein and volume expander, it is marketed in the European Union and requires a prescription. The preparation is used to restore plasma oncotic pressure in appropriate clinical settings.

Human Albumin Csl Behring is indicated for conditions where plasma volume or albumin levels need rapid restoration.

- Treatment of hypovolemia due to acute blood loss, trauma, or dehydration. - Management of hypoalbuminemia associated with chronic liver disease or nephrotic syndrome. - Volume expansion in patients undergoing major surgery, such as cardiac or transplant procedures. - Supportive therapy for extensive burns to maintain intravascular oncotic pressure. - Adjunct in plasma exchange or therapeutic apheresis when albumin replacement is required. - Correction of dilutional hypoalbuminemia during massive fluid resuscitation in critical care settings.

Adverse reactions to Human Albumin Csl Behring are generally infrequent but can range from mild to severe.

Common: - Fever or chills during infusion. - Mild rash or urticaria at infusion site. - Headache or dizziness. - Nausea or vomiting. - Transient hypotension during administration. - Mild itching or pruritus. - Elevated heart rate (tachycardia). - Mild swelling or edema at the infusion site. - Transient increase in serum calcium levels.

Serious: - Anaphylactic or severe allergic reaction. - Acute respiratory distress or bronchospasm. - Hemolysis or renal impairment. - Thromboembolic events such as deep vein thrombosis. - Severe hypertension or hypertensive crisis. - Disseminated intravascular coagulation (DIC). - Cardiac arrest or severe arrhythmias. - Pulmonary edema due to rapid volume expansion.

When using Human Albumin Csl Behring, clinicians should observe several precautions to minimize risk and ensure appropriate patient selection.

- Verify baseline serum albumin and volume status before administration. - Do not administer to patients with a documented allergy to human albumin or other plasma proteins. - Monitor vital signs and fluid balance closely during and after infusion to detect overload. - Use caution in individuals with congestive heart failure, coronary artery disease, or pulmonary hypertension. - Adjust dose or infusion rate in patients with renal impairment or reduced hepatic function. - Infuse slowly (not exceeding recommended rate) to reduce risk of hypotension and anaphylaxis.

Human Albumin Csl Behring may interact with certain medications or clinical conditions; awareness of these interactions helps prevent adverse outcomes.

Avoid: - Concomitant use with other volume expanders that may cause fluid overload. - Administration with drugs that have a high protein binding displacement risk (e.g., warfarin) may alter plasma concentrations. - Use with hyperoncotic agents such as dextran in the same infusion line.

Use with caution: - Concurrent diuretics may increase risk of electrolyte imbalance. - Co-administration with vasopressors may require dose adjustments. - Patients receiving renal replacement therapy may need monitoring of albumin levels. - Use in combination with blood products may affect coagulation parameters.